Table 1 Baseline characteristics of cases and control
Variables | All patients (n = 558) | Controls (n = 279) | Cases (n = 279) | P |
|---|---|---|---|---|
Age, years | 64.13 (57.33–70.59) | 64.13 (57.33–70.57) | 64.12 (57.34–70.72) | 0.976 |
Male, n (%) | 318 (57.0) | 159 (57.0) | 159 (57.0) | 1.000 |
BMI, kg/m2 | 24.54 (22.24–27.18) | 25.04 (22.64–27.34) | 24.34 (21.84–26.73) | 0.033 |
Current smoking, n (%) | 190 (34.1) | 93 (33.3) | 97 (34.8) | 0.925 |
Current drinking, n (%) | 181 (32.4) | 96 (34.4) | 85 (30.5) | 0.551 |
Baseline SBP, mmHg | 168.00 (156.00–181.83) | 165.33 (154.67–180.67) | 170.67 (157.33–183.00) | 0.081 |
Baseline DBP, mmHg | 94.67 (88.00–101.33) | 93.33 (88.0–100.0) | 96.67 (88.00–102.00) | 0.152 |
Treatment group | ||||
Enalapril | 298 (53.4) | 149 (53.4) | 149 (53.4) | 1.000 |
Enalapril-folic acid | 260 (46.6) | 130 (46.6) | 130 (46.6) | |
MTHFR C677T | ||||
CC | 137 (24.6) | 70 (25.1) | 67 (24.0) | 0.626 |
CT | 277 (49.6) | 142 (50.9) | 135 (48.4) | |
TT | 144 (25.8) | 67 (24.0) | 77 (27.6) | |
Triglyceride, mmol/L | 1.43 (1.06–1.99) | 1.47 (1.05–2.09) | 1.38 (1.07–1.93) | 0.295 |
Total cholesterol, mmol/L | 5.54 (4.78–6.22) | 5.54 (4.94–6.21) | 5.54 (4.64–6.22) | 0.407 |
Uric acid, mg/dL | 304.00 (256.00–356.00) | 302.00 (254.50–354.00) | 305.00 (257.00–361.00) | 0.437 |
HDL cholesterol, mmol/L | 1.29 (1.07–1.52) | 1.29 (1.09–1.52) | 1.29 (1.05–1.58) | 0.967 |
Glucose, mmol/L | 5.63 (5.17–6.34) | 5.58 (5.17–6.32) | 5.63 (5.19–6.40) | 0.411 |
Creatinine, mmol/L | 68.70 (58.30–79.28) | 68.70 (57.35–80.05) | 68.70 (58.55–76.95) | 0.703 |
Serum Folic acid, ng/mL | 6.50 (4.87–9.09) | 6.57 (4.66–9.20) | 6.50 (4.94–8.82) | 0.915 |
Homocysteine, μmol/L | 13.72 (11.02–18.82) | 13.70 (10.78–18.27) | 13.72 (11.17–19.25) | 0.289 |
Choline, μg/ml | 8.99 (4.00–13.33) | 7.80 (3.37–12.72) | 9.51 (4.45–13.89) | 0.009 |